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The pyrrolizidine1 and indolizidine1b,2 heterocycles attract 
significant attention due to their biological activity, and synthetic 
challenges that they present.1,2 Typical compounds, shown in 
Figure 1, are natural iminosugars such as hyacinthacines A1/A2 
(1),3 hyacinthacines B1/B2 (2),4 australine  (3) (and its bridgehead 
epimer alexine),5 and castanospermine (4),6 which have attracted 
interest as glycosidase inhibitors. Glycosidases play important 
roles in a number of diseases including many cancers, lysomal 
storage disorders such as Gaucher’s disease, and type II 
diabetes.7 Iminosugars have also gained interest as antiviral 
compounds and antibiotics.7 Also of importance are indolizidine 
alkaloids with alkyl substituents, such as the amphibian derived 
indolizidine 195B (5),8 and related systems.1b,9 These continue to 
attract interest as, for example, inhibitors of nicotinic receptor-
channels and neuromuscular transmission. Of particular interest 
to our work are pyrrolizidines such as bohemamine (6)10 and the 
related de-epoxidised NP25302,11 a rare pyrrolizidin-1-one sub-
class isolated from Actinosporangium sp. and from marine 
Streptomyces sp., members of which have shown significant cell-
cell adhesion inhibitory activity. The structurally related fungal 
derived pyrrolizin-1-ols, epohelmins A and B (7)12 are lanosterol 
synthase inhibitors. Of great relevance to the work reported in 
this paper are systems that have a hydroxy group on the carbon 
atom at the bridgehead such as the antitumour, antibiotic, and 
antiviral clazamycins A and B (8),13 jenamidines B1/B2 (9b) and 
C (10),11a,14 and the synthetic 8a-hydroxy-indolizidines.15 
Jenamidine A1/A2 (9a) inhibits proliferation of leukemia cell line 
K-562 with a reported GI50 of 1.9 g/mL.11a,14 
In this paper, we describe a new synthesis of bridgehead (7a- 
and 8a-) hydroxy-substituted pyrrolizidines and indolizidines 
(14) (see Scheme 1) from the reaction of cyclic imines (11, n = 1 
or 2) with cyclopropenones (12), a process that we believe 
proceeds through the rapid aerial oxidation of a transient 
intermediate (13).  
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Scheme 1: Synthesis of hydroxy-pyrrolizidines and indolizidines 
 
ART I CLE  I NFO  AB ST R ACT  
Article history: 
Received 
Received in revised form 
Accepted 
Available online 
The reaction of cyclic imines (1-pyrrolines and piperidines) with a cyclopropenone leads to 
pyrrolizidines and indolizidines, respectively, each with a hydroxy group on the carbon atom of 
the bridgehead. The cyclopropenone functions as an all-carbon 1,3-dipole equivalent towards the
cyclic imine in this reaction, and the cyclic imines used include polyhydroxylated systems, thus 
allowing access to australine, alexine and hyacinthacine type compounds. The pyrrolizidine 
products contain the core of the jenamidine and bohemamine natural products which are of 
interest as cell-proliferation inhibitors and cell-cell adhesion inhibitors. 
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Figure 1: Indolizidine and pyrrolizidine natural products 
 
The reaction of cyclic imines with cyclopropenones is a 
process that we have studied previously using cyclic imines (15) 
that are 2-substituted (X = O, S; R = Me, Et),16 and we have 
shown that a range of alkoxy- and alkylthio-substituted cyclic 
imines react to give bicyclic systems (16) in the azetidinopyrrole 
(n = 0),  pyrrolizidine (n = 1), indolizidine (n = 2) and 
pyrroloazepine (n = 3) classes, as summarized in Scheme 2. 
 
Scheme 2: The use of 2-substituted cyclic imines 
  
In order to produce compounds with a bridgehead hydrogen, a 
feature common to natural products (1)-(5), (7) and (9a), we 
sought to explore the reactions of 2-unsubstituted cyclic imines 
with cyclopropenones, and report the results of this study herein. 
We began our study with the synthesis of the imines (17)-(21) 
shown in Figure 2, with the ultimate goal of natural product 
syntheses. 
 
Figure 2: Cyclic imines selected for study 
 
Imine (17) was selected to allow, after reaction with an 
appropriate cyclopropenone, direct access to analogues (13) (see 
Scheme 1) of the jenamidines (9a) and, after manipulation of the 
enone functionality and/or side-chains, access to jenamidines 
A1/A2 themselves. Imine (17) was accessed by cyclisation of 4-
aminobutyraldehyde diethyl acetal which was stabilised as its 
zinc iodide complex.17 Imine (18) was chosen ultimately to 
explore access to hyacinthacines B1/B2 (2), but also to a range of 
potentially interesting hydroxymethyl pyrrolizidines, and we 
synthesised it as a single enantiomer using an aza-Wittig based 
route starting from L-glutamic acid exactly as described by Banfi 
et al.18 Imines (19)19 and (20)20 were chosen as they offer a 
potential route into indolizidines such as (5) and analogues, and 
these imines were made by an adaptation of reported N-
chlorination-dehydrochlorination sequences.19,20 Imine (21) was 
chosen due to its ready availablity21 and its potential to allow 
access to polyhydroxylated pyrrolizidines, including 
hyacinthacine A2 (1) and australine (3) and/or their epimers, after 
pyrrolidinone reduction and benzyl deprotection. 
With imines (17)-(21) synthesised as described,17-21 we started 
to explore their reactivity towards diphenylcyclopropenone (12a; 
R1 = R2 = Ph), phenylcyclopropenone (12b; R1 = H, R2 = Ph) and 
cyclopropenone (12c; R1 = R2 = H). Diphenylcyclopropenone is 
commercially available, whilst phenylcyclopropenone16c,22 and 
cyclopropenone23 were synthesised as described in the literature. 
Cyclopropenones have attracted recent interest as all-carbon 1,3-
dipole equivalents,16,24 as alkyne precursors in click processes,25 
and as novel catalytic platforms.26 The first cyclopropenone 
reactions performed in our current study, as shown in Scheme 3, 
were those of imines (17) and (20) (the most readily available) 
with commercially available diphenylcyclopropenone (12a). 
These two reactions occurred extremely smoothly, but we were 
surprised to discover an extra 16 mass units in the mass spectra 
of the products. This, together with the absence of a C-H signal 
(the expected bridgehead C-H) in each of the 13C and 1H-NMR 
spectra, the presence of an additional quaternary carbon (13C) and 
a clear OH in the infra-red and 1H-NMR spectra, led us to believe 
that the products that had formed were the alcohols (14a) and 
(14b), rather than the expected compounds (13a) and (13b).27 
Alcohols (14a) and (14b) were isolated in 61% and 84% yields, 
respectively. Compound (14a) was crystalline and found to be 
suitable for study by X-ray crystallography (Figure 3),28 which 
confirmed that the structure was that predicted. We assume that 
the expected adducts (13), via their enol tautomers (22), are 
unusually susceptible to aerial oxidation, and that the initial 
product of oxidation, the hydroperoxide (23) (Scheme 3), 
undergoes O-O cleavage to form the isolated alcohols (14). It is 
known that enols and their derivatives can undergo easy 
oxidation to -hydroxy ketones29 even in the absence of catalyst, 
photosensitisor or photoinducer.30 Similarly, 3-hydroxypyrroles 
have been shown to undergo photooxidation to give highly 
reactive hydroperoxides which are easily intercepted in 
synthetically useful processes,31 lending further credence to the 
involvement of species (22) / (23). We cannot rule out the 
possibility that cyclopropenones, cyclic enaminones or their 
hydroxypyrrole tautomers, behave as photosensitisors or 
photoinducers. In other catalyst-free aerobic oxidation systems 
involving enols, it has been noted that free-radical traps fail to 
halt the reaction or give ESR signals, and that intermediate 
peroxides can be detected.30 It is also possible that intermediate 
(23) acts as an oxidising agent towards compound (22) in order 
to produce the final product (14).32 Further mechanistic studies 
are underway in our laboratory. 
 
N
X
HO
H
HO
Y
N
HO
HO
HO H OH
N
H
N
H OH
C5H11
H N
NHHO
N
O
HN
X
O
N
O
HN
HO
O
OH
O
3
5
1 A2: Y = OH, X = H
   A1: Y = H, X = OH
4
7
9a A1/A2: X = H9b B1/B2: X = OH 10
N
HO
HO
H
HO X Y
2 B2: X = CH2OH, Y = H
   B1: X = H, Y = CH2OH
Cl
N
O
O
HN
6
O
8
OH
NHO
H
HO
HO OH
N( )n
O
R1 R2
+ N( )n
O
R2
R1
RX15 12
XR
16
n = 0, 1, 2, 3
X = O or S
R = Me or Et
N NN OTBDMS
N
BnO OBn
BnO
N
Me
17 18 19
2120
  
 
 
 
 
 
 
 
Scheme 3: Synthesis of 7a- / 8a-hydroxy-indolizidines and pyrrolizidines 
 
 
Figure 3: X-ray crystallographic structure of compound (14a)  
 
Other imines and cyclopropenones behaved in the same 
manner and the results are summarised in Table 1.27 Imines (17), 
(18) and (19) reacted with phenylcyclopropenone to give 
compounds (14c), (14d) and (14e) as single regioisomers (R1 = 
H, R2 = Ph; easily identified by HMBC), presumably due to the 
attack of the cyclopropenone (12) by the imine at the least 
hindered carbon, as we observed when working with this and 
other mono-substituted cyclopropenones before.16 With imines 
(18), (20) and (21), the products (14e-i) were isolated as single 
diastereoisomers. Each of the pyrrolizidines (14e-g) showed the 
CH2OTBDMS and OH groups to be cis to each other (nOesy). 
We were unable to determine the relative stereochemistry in 
indolizidine (14h), but by analogy to that observed in compounds 
(14e-g), we have tentatively assigned the OH and Me groups as 
cis to each other. Pyrrolizidine (14i) was formed from the chiral 
pool derived enantiopure21 imine (21). The stereochemistry of the 
new stereocentre – the bridgehead OH – was established by 
nOesy which showed the OH to be cis to the adjacent OBn and 
cis to the CH2OBn group, and also confirmed the relative 
stereochemistry of the other chiral centres.  In the case of 
compound (14i), the enol (22) was the initial isolated product but 
underwent quantitative conversion (CDCl3, NMR tube) into the 
7a-hydroxypyrrolizidine (14i) over 24 hours. Whilst this is 
significant in terms of the proposed mechanism in Scheme 3, this 
was the only system where we were able to observe enol 
formation. The use of imine (21) has allowed us to produce 
systems that are closely related to the hyacinthacine, australine 
and alexine natural products (1)-(3). The 7a-
hydroxypyrrolizidines (14, n = 1) produced from the pyrrolines 
(17), (18) and (21) have a core structure that is closely related to 
the 7a-hydroxypyrrolizidine natural products (8), (9b) and (10). It 
is of note that natural product (9a) has a hydrogen at the 
bridgehead position and this presents the intriguing possibility 
that the jenamidine B1/B2 (9b) may arise from jenamidine A1/A2 
(9a) through the type of mechanism presented in Scheme 3. 
Natural products (8) and (10) may have similar origins,32 and we 
are actively pursuing this possibility. 
Current studies in our laboratory are focusing upon the 
synthesis of hyacinthacine, australine, alexine and 
castanospermine (and their epimers), and their 7a-/8a-hydroxy 
analogues. A programme of study focused on the synthesis of 8a-
hydroxy analogues of the alkylated indolizidines (such as 
compound 5) is also underway alongside our continuing studies 
on the jenamidines. 
 
Table 1: 7a-/ 8a-Hydroxy-indolizidines and pyrrolizidines from 
cyclopropenones (12) and imines (17)-(21)27 
 
Product n Imine  12, R1 and R2 Yield (%)  
14a 1 17 R1 = R2 = Ph 61 
14b 2 19 R1 = R2 = Ph 84 
14c 1 17 R1 = H,  R2 = Ph 26 
14d 2 19 R1 = H,  R2 = Ph 57 
14e 1 18 R1 = H,  R2 = Ph 36 
14f 1 18 R1 = R2 = H 30 
14g 1 18 R1 = R2 = Ph 37 
14h 2 20 R1 = R2 = H 33 
14i 1 21 R1 = R2 = H 34 
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h and then warming to room temperature over 4 h. Compound 
(14i):  IR: υmax (neat, cm-1):  3359 (b, m), 3062 (w), 3031 (m), 
2926 (m), 2867 (m), 1688 (s), 1538 (s), 1454 (m), 1362 (m), 1206 
(m), 1111 (s), 738 (m), 699 (m); 1H NMR (500 MHz, CDCl3), δH: 
3.44 – 3.47 (1H, ddd, J 7.2, 5.9, 4.7, CHN), 3.53 (1H, dd, J 7.2, 
9.4, CHCH2OBn), 3.58 (1H, dd, J 4.7, 9.4, CHCH2OBn), 3.82 
(1H, d, J 6.8, C(OH)CHOBn), 3.89 (1H, br s, OH), 4.17 (1H, dd, J 
5.9, 6.8, CH(CHOBn)2), 4.49 (1H, d, J 11.7, OCH2Ph), 4.51 (1H, 
d, J 11.9, OCH2Ph), 4.55 (1H, d, J 11.9, OCH2Ph), 4.61 (1H, d, J 
11.7, OCH2Ph), 4.66 (1H, d, J 11.7, OCH2Ph), 4.97 (1H, d, J 11.7, 
OCH2Ph), 5.23 (1H, d, J 3.7, C=CH), 7.17 – 7.19 (2H, m, ArH), 
7.28 – 7.37 (13H, m, ArH), 7.76 (1H, d, J 3.7, HC=C); 13C NMR: 
δc (125 MHz, CDCl3): 62.90 (CH), 71.58 (CH2), 72.50 (CH2), 
73.06 (CH2), 73.28 (CH2), 82.00 (CH), 87.07 (CH), 92.02 (C), 
102.24 (CH), 127.36 (CH), 127.47 (CH), 127.51 (CH), 127.57 
(CH), 127. 75 (CH), 128.05 (CH), 128.07 (CH), 128.13 (CH), 
128.14 (CH), 136.68 (C), 137.18 (C), 137.30 (C), 168.75 (CH), 
201.73 (C=O); m/z (electrospray) HRMS: calcd for C29H29NO5 + 
Na+ = 494.1938, found: 494.1947 [2 ppm error].  
28. Crystallographic data has been deposited at the Cambridge 
Crystallographic Data Centre as a CIF deposition with file number 
CCDC 873002. Copies of these data can be obtained free of 
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